The present authors performed an open up-label pilot analyze that administered psilocybin to fifteen therapy-resistant tobacco/nicotine-dependent people who smoke, during the context of cognitive behavioral therapy for smoking cessation [fifty eight]. Contributors were administered ~0.29 mg/kg oral psilocybin within the participant’s goal date to